Oslo, Norway

Maria Eb Berstad

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignees: Rab Diagnostics as, Other. Active years: 2022-2026.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Maria Eb Berstad: Innovator in Cancer Therapy

Introduction

Maria Eb Berstad is a prominent inventor based in Oslo, Norway. She has made significant contributions to the field of cancer therapy through her innovative research and development. Her work focuses on improving the diagnosis and treatment of cancer, which is a critical area of medical research.

Latest Patents

Maria holds a patent related to the diagnosis and treatment of cancer. This invention encompasses compositions and methods for cancer therapy, particularly those that utilize cancer biomarkers. The patent specifically addresses the prediction of a subject's response to cancer therapies, which can greatly enhance treatment outcomes.

Career Highlights

Throughout her career, Maria has demonstrated a commitment to advancing cancer research. Her innovative approaches have positioned her as a key figure in the medical community. With her expertise, she continues to explore new avenues for effective cancer treatment.

Collaborations

Maria has collaborated with notable professionals in her field, including Anette Weyergang and Kristian Berg. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in cancer therapy.

Conclusion

Maria Eb Berstad is a trailblazer in the realm of cancer therapy, with her patent and collaborative efforts contributing to significant advancements in the field. Her work exemplifies the impact of innovation in improving patient care and treatment outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…